Share-Based Compensation (Tables)

9 Months Ended

Mar. 31, 2015

Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding

A summary of the stock option activity under the Company’s plans for the nine months ended March 31, 2015 is as follows:


	Number of shares		Weighted average exercise price
Options outstanding at June 30, 2014		14,238,183	$	23.30
Options granted		1,000	$	37.17
Less:
Options exercised		1,144,275	$	20.20
Options canceled or expired		343,161	$	25.70

Options outstanding at March 31, 2015		12,751,747	$	23.51

Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units Outstanding

A summary of the RSU activity under the Company’s plans for the nine months ended March 31, 2015 is as follows:


	Number of shares		Weighted average grant date fair value
RSUs outstanding at June 30, 2014		—	$	—
RSUs granted		1,245,833	$	37.67
Less:
RSUs vested		19,500	$	34.22
RSUs canceled		100,283	$	38.12

RSUs outstanding at March 31, 2015		1,126,050	$	37.68

Schedule of Share-Based Compensation Recognized in Consolidated Statements of Income and Comprehensive Income

Share-based compensation expense recognized and included in the condensed consolidated statements of income and comprehensive income was allocated as follows:


(In thousands)	Three months ended March 31,				Nine months ended March 31,
	2015		2014		2015		2014
Cost of molecular diagnostic testing	$	224	$	207	$	671	$	639
Cost of pharmaceutical and clinical services		104		75		387		212
Research and development expense		1,201		3,042		3,218		4,670
Selling, general, and administrative expense		11,016		10,316		27,296		21,911

Total share-based compensation expense	$	12,545	$	13,640	$	31,572	$	27,432